Victoria Demby, Ph.D.

Over 25 years of regulatory leadership spanning diverse therapeutic areas, including oncology, neurology, immunology, cell & gene therapy, and beyond. Successfully led multiple INDs, NDAs, and global marketing applications. Secured BTD, RMAT, PRIME designations and managed complex FDA, EMA, PMDA interactions. Played a key role in Adlai Nortye’s IPO and held senior regulatory roles at GSK, Merck, and BMS.